Rate of subsequent emergency department and inpatient hospital visits among individuals with cannabis‐associated diagnoses: A retrospective cohort study of Arizona, USA hospital discharge data
Addiction · 2026-11-09
DOI: 10.1111/add.70705 ↗Abstract
Abstract Aims To track people with a cannabis‐associated diagnosis during a hospital visit and examine rates of subsequent hospital visits over one year, including visits with mental health‐ and substance use‐associated diagnoses. Design Retrospective cohort study of Arizona, USA hospital discharge data. Patients were observed for one year before and after their 2018 index visit to capture hospital encounters with mental health‐ and substance use‐associated diagnoses. Setting Data were patient‐level emergency department and inpatient hospital records from Arizona, USA 2017–2019. Participants Four groups of patients were identified based on diagnoses during their index visit in 2018. These included people who had 1) a cannabis‐associated diagnosis and a co‐occurring mental health‐associated diagnosis (C+/MH+; n = 16 699), 2) a cannabis‐associated diagnosis but not a mental health‐associated diagnosis (C+/MH‐; n = 21 406), 3) a mental health‐associated diagnosis but not a cannabis‐associated diagnosis (C‐/MH+; n = 230 519), and 4) neither a cannabis‐associated nor a mental health‐associated diagnosis (C‐/MH‐; n = 1 096 939). Measurements Records included diagnosis codes from the International Classification of Diseases, 10th Revision, Clinical Modification (ICD‐10‐CM), which were used to identify cannabis‐associated diagnoses, other substance use‐associated diagnoses, and mental health‐associated diagnoses. In analyses predicting subsequent hospital visits, covariates included demographic factors; index visit month; total number of past‐year visits, visits with a mental health‐associated diagnosis, and visits with a substance use‐associated diagnosis; concurrent (to the index visit) non‐cannabis substance use‐associated diagnosis and the Elixhauser readmission index. Results After adjusting for covariates, people with a cannabis‐associated diagnosis during their index visit in 2018 had 1.23 times the rate of subsequent hospital visits as those without a cannabis‐associated diagnosis (99.8% confidence interval (CI) [1.20, 1.26]), 2.74 times the rate of subsequent visits with a mental health‐associated diagnosis (99.8% CI [2.64, 2.84]), and 1.76 times the rate of subsequent visits with a substance use‐associated diagnosis (99.8% CI [1.69, 1.83]). Elevated visit rates were observed among individuals with a cannabis‐associated diagnosis, regardless of whether they had a concurrent mental health‐associated diagnosis, though associations were stronger among those without a concurrent mental health‐associated diagnosis. Summary A cannabis‐associated diagnosis during a hospital visit appears to signal risk for higher rates of subsequent hospital use.
EUVIMED